Episurf Medical Ab Class B · OMXSTO:EPIS_B
Episurf Medical Ab Class B — Shareholder Meeting (April 2024)
17 slides from Episurf Medical Ab Class B's shareholder meeting presentation, April 2024
Slide 1: Annual General Meeting 2024
Annual General Meeting 2024 Stockholm, April 2024 episurf.com episurf.com
Slide 2: Episealer – a comprehensive technology platform
Episealer® – a comprehensive technology platform Knee Lower extremities Imaging platform • State-of-the-art imaging platform for Product patient selection Episealer® Knee Episealer® Patellofemoral Episealer® Talus Episealer® MTP-system • Used for design and System (with associated osteotomy guide) p
Slide 3: Key regulatory milestones
Key regulatory milestones Last Twelve months, Episealer® surgeries have been performed in more than 20 countries worldwide North America EMEA APAC • Following a strategic decision in 2017 to expand the geographical focus, Episurf has established a global presence • During LTM, Episealer surgeries ha
Slide 4: Episealer – accelerating adoption across geographies
Episealer® – accelerating adoption across geographies Close to 2,000 surgeries have taken place, with close to 500 patients having Episealer® implants for >5 years >10 Years 6 Years since >5 Years 474 Cumulative number of Episealer® implant surgery with >4 Years 687 orders from Jan. 2013 until Dec.
Slide 5: Financial highlights
Financial highlights Year-end report 1 January – 31 December 2023 Gross order intake, LTM growth Surgeries per year 2020 2021 2022 2023 56% 500 53% 46% 438 400 39% 40% 36% +42.2% 306 26% 300 281 255 18% 19% 16% 11% 200 11% 7% 5% 5% 100 0% -4% -- J F M A M J J A S O N D Early technology establishment
Slide 6: Financial highlights (cont'd)
Financial highlights (cont’d) Year-end report 1 January – 31 December 2023 Q4 2023 vs. Q4 2022 FY 2023 vs. 2022 Q4 2023 Update +56.3% +40.9% Continued stable growth despite restructuring of commercial 11,1 organization, and satisfactory start in the US. 3,1 During the fourth quarter, 119 surgeries w
Slide 7: Restructuring program 2023
Restructuring program 2023 • Increased focus towards distributor sales − Targeted cost reduction of SEK 25m p.a. (SEK 20m achieved as of Q4 report) • Maintain a global reach • Open to partnerships – market participants want our products! 7
Slide 8: Global distributor network
Global distributor network One of two levers for driving awareness and adoption amongst surgeons ✓ Targeting distributors with strong Time should be spent on the patient… local presence and close ties to surgeon customers ”It is that our salesforce, like most orthopaedic salesforces, spends about 40
Slide 9: First commercial case in the US
First commercial case in the US The first surgery with the Episealer® Patellofemoral System was performed by Dr. Gary Levengood in Atlanta, Georgia, on October 5th 2023 • From our internal chat-system: − “KZWG-01 in place this morning. Lots of firsts with this one. First US commercial case, first pa
Slide 10: Partial Knee Meeting 2024
Partial Knee Meeting 2024 Abstract presentation by Dr Francesca de Caro • Patients treated by Prof. Peter Verdonk, AZ Monica, Antwerp • N=22 • Mean follow-up 43.7 months (range 23-91) • VAS improved from 68 to 37 • Aggregated KOOS increased from 46 to 67 • Implant survival rate 88% First 10- year da
Slide 11: The Oxford Knee – use at a British clinic
The Oxford Knee – use at a British clinic Presentation from 2017 by Mr. Jon Waite, South Warwickshire NHS. 11
Slide 12: Episealer roll-out in the US underway
Episealer® roll-out in the US underway Securing reach in the US Episealer Patellofemoral System • • 510(k) cleared in December 2022, commercially launched H2 2023 ASP: USD ~4,500 23 40-50 Distributors Target no. of distributors • Focus on securing VAC approvals and initial customers across the count
Slide 13: Capturing the European & RoW near-term opportunity
Capturing the European & RoW near-term opportunity Episealer® Knee Expanding distributor network • Launched, surgeons leading adoption in selected European Sweden, Norway, Denmark, Switzerland, UK, • • countries (Germany, Belgium & UK etc.) Technology adoption and clinical acceptance prioritized thr
Slide 14: Management, Board of Directors & Senior Advisor
Management, Board of Directors & Senior Advisor Management Board of Directors & Senior Advisor Pål Ryfors, CEO Ulf Grunander B shares: 3,000,000 Employee Options: 872,734 Chairman of the Board Performance Options: 2,627,431 B shares: 381,000 Warrants: 1,661,427 Years with Episurf: 8 Leif Ryd Veronic
Slide 15: Shareholders
Shareholders Shareholders Shares (000s) % holding December 2023 A B votes capital 1 Health Runner AB (Ilija Batljan) -- 34 771 13,0% 13,0% 2 Rhenman Partners -- 12 667 4,7% 4,7% 3 Fjärde AP-Fonden -- 12 537 4,7% 4,7% 4 Sebastian Jahreskog -- 11 993 4,5% 4,5% 5 Tredje AP-Fonden -- 9 980 3,7% 3,7% 6 L
Slide 16: Strategy 2024-2026 milestones and market opportunity
Market 2024 2025 2026 Key indicator opportunity Episealer® Commercialization First cases ✓ ~USD 0.3bn Patellofemoral S. 510(k) ✓ Episealer® MTP-System 510(k) Commercialization ~USD 0.4bn submission Strategy 2024 - 2026 + Episealer® Knee RoW Commercialization ✓ ~USD 0.4bn ~40% growth in user base Epi
Slide 17: Medical
© EPISURF Medical